Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Scholar Rock (NASDAQ: SRRK) announced it will host a conference call to discuss third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. The company, which focuses on developing treatments for spinal muscular atrophy, cardiometabolic disorders, and other diseases involving protein growth factors, will make the audio webcast available on their investor relations website. Participants can register online to join via telephone or web.
Scholar Rock (NASDAQ: SRRK) ha annunciato che ospiterà una conference call per discutere i risultati finanziari del terzo trimestre 2024 e fornire un aggiornamento aziendale martedì 12 novembre 2024, alle 8:15 ET. L'azienda, che si concentra sullo sviluppo di trattamenti per la atrofia muscolare spinale, disturbi cardiometabolici e altre malattie legate ai fattori di crescita proteici, renderà disponibile il webcast audio sul proprio sito web delle relazioni con gli investitori. I partecipanti possono registrarsi online per unirsi tramite telefono o web.
Scholar Rock (NASDAQ: SRRK) anunció que llevará a cabo una conferencia telefónica para discutir los resultados financieros del tercer trimestre de 2024 y ofrecer una actualización sobre el negocio el martes 12 de noviembre de 2024, a las 8:15 a.m. ET. La empresa, que se centra en desarrollar tratamientos para la atrofia muscular espinal, trastornos cardiometabólicos y otras enfermedades relacionadas con factores de crecimiento proteicos, pondrá a disposición la transmisión de audio en su sitio web de relaciones con inversores. Los participantes pueden registrarse en línea para unirse por teléfono o por la web.
스콜라 락(Scholar Rock) (NASDAQ: SRRK)은 2024년 3분기 재무 결과를 논의하고 사업 업데이트를 제공하기 위해 이날 2024년 11월 12일 화요일 오전 8:15(동부 표준시)에 컨퍼런스 콜을 진행할 것이라고 발표했습니다. 이 회사는 척수성 근육 위축증, 심혈관 대사 장애 및 단백질 성장 인자와 관련된 기타 질병에 대한 치료법 개발에 집중하고 있으며, 투자자 관계 웹사이트에서 오디오 웹캐스트를 제공할 예정입니다. 참가자는 온라인으로 등록하여 전화 또는 웹을 통해 참여할 수 있습니다.
Scholar Rock (NASDAQ: SRRK) a annoncé qu'il organisera une conférence téléphonique pour discuter des résultats financiers du troisième trimestre 2024 et fournir une mise à jour sur l'entreprise le mardi 12 novembre 2024, à 8h15 ET. L'entreprise, qui se concentre sur le développement de traitements pour l'atrophie musculaire spinale, les troubles cardiométaboliques et d'autres maladies impliquant des facteurs de croissance protéiques, mettra à disposition le webinaire audio sur son site de relations avec les investisseurs. Les participants peuvent s'inscrire en ligne pour rejoindre par téléphone ou sur le web.
Scholar Rock (NASDAQ: SRRK) kündigte an, dass am Dienstag, den 12. November 2024, um 8:15 Uhr ET eine Telefonkonferenz stattfinden wird, um die Finanzergebnisse des dritten Quartals 2024 zu erörtern und ein Unternehmensupdate zu geben. Das Unternehmen, das sich auf die Entwicklung von Therapien gegen spinale Muskelatrophie, kardiometabolische Erkrankungen und andere Krankheiten, die mit Wachstumsfaktoren für Proteine in Verbindung stehen, konzentriert, wird das Audio-Webcast auf seiner Investor-Relations-Website zur Verfügung stellen. Teilnehmer können sich online registrieren, um per Telefon oder über das Web teilzunehmen.
- None.
- None.
To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. An archived replay of the webcast will be available on the Company’s website for approximately 90 days.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101586315/en/
Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-5995
Source: Scholar Rock
FAQ
When will Scholar Rock (SRRK) report Q3 2024 earnings?
How can I access Scholar Rock's (SRRK) Q3 2024 earnings call?